Skip to main content
Fig. 7 | Nano Convergence

Fig. 7

From: Cancer nanotechnology: current status and perspectives

Fig. 7

A Conjugation of an anti-IgG (Fc specific) antibody (αFc) to nanoparticle (αFc-NP). B Two types of immunomodulating monoclonal antibodies (mAbs) targeting effector cells and tumor cells immobilized onto αFc-NP to create immunomodulating nanoadaptors (imNA). C imNAs were validated in T cell-, natural killer cell- and macrophage-mediated antitumor immune responses in multiple murine tumor models. Reprinted with permission, [218] https://doi.org/10.1038/s41467-021-21497-6

Back to article page